Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.04
- Piotroski Score 3.00
- Grade Outperform
- Symbol (SUNL)
- Company Sunlight Financial Holdings Inc.
- Price $0.25
- Changes Percentage (-34.21%)
- Change -$0.13
- Day Low $0.19
- Day High $0.36
- Year High $41.20
Sunlight Financial Holdings Inc. operates a business-to-business-to-consumer technology-enabled point-of-sale financing platform in the United States. Its platform is used to provide secured and unsecured loans for homeowners originated by third-party lenders to purchase and install residential solar energy systems, and other home improvements. The company was founded in 2014 and is based in Charlotte, North Carolina.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/13/2023
- Fiscal Year End N/A
- Average Stock Price Target $1,000.00
- High Stock Price Target $1,000.00
- Low Stock Price Target $1,000.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$93.00
- Trailing P/E Ratio -0.0026881720430108
- Forward P/E Ratio -0.0026881720430108
- P/E Growth -0.0026881720430108
- Net Income $-511,936,000
Income Statement
Quarterly
Annual
Latest News of SUNL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
UK's NICE Says Alzheimer's Disease Drug Kisunla Is Not Cost-Effective
The UK approved the Alzheimer's drug Kisunla, facing reimbursement challenges due to cost. NICE requires cost-effective benefits for NHS reimbursement. Kisunla targets beta amyloid and tau plaque in t...
By Forbes | 6 days ago -
Solar Cells That Work Without Sunlight Open Way For Self-Powered Devices
Exeger, a Swedish company, has developed solar cells that can generate power from indoor light sources. Their innovative Powerfoyle cells are integrated into various products, reducing the need for di...
By Forbes | 1 week ago -
Lilly's Kisunla does not demonstrate "good value" for UK's NHS
Eli Lilly's Alzheimer's drug, Kisunla, faces NICE rejection in the UK due to concerns about cost-effectiveness and uncertainties about long-term benefits. The drug, like Leqembi, targets amyloid plaqu...
By Yahoo! Finance | 2 weeks ago
